| __timestamp | Corcept Therapeutics Incorporated | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 34916000 | 40786000 |
| Thursday, January 1, 2015 | 36949000 | 47876000 |
| Friday, January 1, 2016 | 45240000 | 52035000 |
| Sunday, January 1, 2017 | 62416000 | 55348000 |
| Monday, January 1, 2018 | 81289000 | 65276000 |
| Tuesday, January 1, 2019 | 100359000 | 82720000 |
| Wednesday, January 1, 2020 | 105326000 | 89118000 |
| Friday, January 1, 2021 | 122356000 | 181193000 |
| Saturday, January 1, 2022 | 152848000 | 174078000 |
| Sunday, January 1, 2023 | 184259000 | 184232000 |
Igniting the spark of knowledge
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Corcept Therapeutics Incorporated and Veracyte, Inc. over the past decade. From 2014 to 2023, both companies have shown a significant upward trend in their SG&A spending, reflecting their growth and strategic investments.
Corcept Therapeutics saw its SG&A expenses grow by over 400%, starting from approximately $35 million in 2014 to nearly $184 million in 2023. Similarly, Veracyte, Inc. increased its spending by a remarkable 350%, from around $41 million to $184 million in the same period. This parallel growth trajectory highlights the competitive nature of the biotech industry, where strategic spending is key to maintaining market position and driving innovation.
As these companies continue to expand, their SG&A expenses will be a critical indicator of their operational strategies and market ambitions.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated Trends and Insights
Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Insmed Incorporated and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Corcept Therapeutics Incorporated and Veracyte, Inc.
Corcept Therapeutics Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Alpine Immune Sciences, Inc. and Veracyte, Inc.
PTC Therapeutics, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?
Veracyte, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and ImmunityBio, Inc.